The maintenance of effect with tildrakizumab over 5 years is independent of baseline characteristics: pooled analysis of the phase 3 studies reSURFACE 1 and reSURFACE 2 in patients with moderate to severe psoriasis

被引：0
|
作者：
Thaci, Diamant [1 ]
Piaserico, Stefano [2 ]
Diemert, Sebastian [3 ]
Torres, Tiago [4 ]
机构：
[1] Univ Lubeck, Inst & Exzellenzzentrum Entzundungsmed, Lubeck, Germany
[2] Univ Padua, Dept Med, Unit Dermatol, Padua, Italy
[3] Almirall Hermal GmbH, Reinbek, Germany
[4] Ctr Hosp Univ Porto, Dept Dermatol, Porto, Portugal
来源：
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT | 2023年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P071
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [31] Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: Results from a 5-year extension of a phase 3 study (reSURFACE 1)
    Imafuku, Shinichi
    Nakagawa, Hidemi
    Igarashi, Atsuyuki
    Morita, Akimichi
    Okubo, Yukari
    Sano, Shigetoshi
    Tada, Yayoi
    Nemoto, Osamu
    Rozzo, Stephen J.
    Kawamura, Masaki
    Ohtsuki, Mamitaro
    JOURNAL OF DERMATOLOGY, 2021, 48 (06): : 844 - 852
  • [32] Safety of tildrakizumab in patients with preexisting metabolic syndrome: Long-term data from the post hoc analysis of two phase 3 clinical studies (reSURFACE 1 and reSURFACE 2)
    Lebwohl, Mark G.
    Mehta, Nehal N.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, M. Alan
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
  • [33] Application of the Statistical Method to Convert Published PASI 50/75/90/100 into Absolute PASI Response Rate in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Tildrakizumab Based on Data from the Two Pivotal Phase 3 Studies reSURFACE 1 and reSURFACE 2
    Dykukha, Igor
    Schoenenberger, Andreu
    Kasujee, Ismail
    Mrowietz, Ulrich
    Vonthein, Reinhard
    DERMATOLOGY, 2022, 238 (05) : 910 - 918
  • [34] Long-term efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who were partial responders or nonresponders to etanercept: Post hoc analysis through 5 years from the reSURFACE 2 phase 3 trial
    Thaci, Diamant
    Griffiths, Christopher E. M.
    Iversen, Lars
    Peserico, Andrea
    Pau-Charles, Ignasi
    Blauvelt, Andrew
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB119 - AB119
  • [35] Long-term efficacy of tildrakizumab 100 mg by PASI 75/90/100 and PGA in a pooled analysis of reSURFACE 1 and reSURFACE 2 through up to 4 years of treatment
    Jackson, J. Mark
    Alexis, Andrew
    Kucera, Kristine
    Mendelsohn, Alan M.
    Rozzo, Stephen J.
    Gorelick, Joseph
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB79 - AB79
  • [36] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 2
    Gooderham, M.
    Papp, K.
    Blauvelt, A.
    Thaci, D.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Reich, K.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 62
  • [37] Efficacy and safety of long-term tildrakizumab for moderate to severe chronic plaque psoriasis: 3-year results from reSURFACE 1
    Tyring, S.
    Spelman, L.
    Igarashi, A.
    Ohtsuki, M.
    Li, Q.
    Mendelsohn, A.
    Parno, J.
    Guenthner, S.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2019, 60 : 61 - 61
  • [38] Safety and tolerability of tildrakizumab, an anti-interleukin-23p19 monoclonal antibody, in patients with chronic plaque psoriasis over two years of treatment: Results from long-term extensions of two phase III clinical studies (reSURFACE 1 and reSURFACE 2)
    Reich, Kristian
    Papp, Kim
    Thaci, Diamant
    Kimball, Alexa B.
    Sinclair, Rodney
    Tyring, Stephen K.
    Cichanowitz, Nicole
    Li, Qing
    la Rosa, Carmen
    Blauvelt, Andrew
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB251 - AB251
  • [39] Time to relapse in patients with moderate to severe psoriasis who were tildrakizumab responders at week 28: Post hoc analysis through 64 weeks from the reSURFACE 1 trial
    Reich, Kristian
    Carrascosa, Jose-Manuel
    Fumero, Emilio
    Schoenenberger Lopez, Andreu
    Lebwohl, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB11 - AB11
  • [40] Tildrakizumab efficacy by metabolic syndrome status in psoriasis: Post hoc analysis of 3-year data from the phase 3 reSURFACE 1 study
    Lebwohl, Mark G.
    Gottlieb, Alice B.
    Mendelsohn, Alan M.
    Parno, Jeff
    Rozzo, Stephen J.
    Menter, Martin
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB51 - AB51
12345